Women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy, according to a new study published in Clinical Cancer Research* today.
Researchers - funded by Cancer Research UK** and based at Queen Mary University London - examined samples from 60 women *** with ovarian cancer and found that chemotherapy given prior to surgery activates specialised immune cells called T cells within the tumour.